Get the Stockscreener App
6.23
2.66%
-0.17
After Hours:
6.23
Puma Biotechnology Inc stock is traded at $6.23, with a volume of 438.75K.
It is down -2.66% in the last 24 hours and down -8.25% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$6.40
Open:
$6.33
24h Volume:
438.75K
Relative Volume:
1.01
Market Cap:
$313.94M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
10.21
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
-18.03%
1M Performance:
-8.25%
6M Performance:
+23.86%
1Y Performance:
+75.99%
1-Day Range:
$6.14
$6.385
1-Week Range:
$5.50
$6.8599
52-Week Range:
$2.575
$7.68
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
6.23 | 322.50M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotech (PBYI) Earnings Call Transcript - AOL.com
Puma Biotech at TD Cowen Conference: Strategic Growth and Financial Discipline - Investing.com Canada
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2025 Earnings Call Transcript - Insider Monkey
PBYI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Puma Biotechnology (PBYI) Margin Resilience Tests Bearish Earnings Forecasts In FY 2025 Results - Sahm
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen - MarketBeat
PBYI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View - TradingView
Puma Biotechnology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-02-27 - Seeking Alpha
Earnings call transcript: Puma Biotechnology Q4 2025 beats forecasts with strong revenue growth - Investing.com India
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology Q4 Earnings Call Highlights - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Puma Biotechnology Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Puma Biotech: Fourth Quarter Earnings Overview - Bitget
Puma Biotechnology (PBYI) Releases Q4 2025 Earnings: Revenue Beats, EPS Tops Estimates but Cash Falls - Quiver Quantitative
Puma Biotechnology Q4 Earnings Report: What Investors Need to Know - Benzinga
Breast and lung cancer trials move ahead as Puma books $31.1M profit - Stock Titan
Puma Biotechnology Hits New 52-Week High of $7.68, Up 120% - Markets Mojo
Puma Biotechnology Inc expected to post earnings of 23 cents a shareEarnings Preview - TradingView
Analyst Downgrade: Is The Oncology Institute Inc Equity Warrants ROE strong enoughWeekly Trend Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference - BioSpace
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference - lelezard.com
Dip Buying: Whats the profit margin of BBDCJuly 2025 Price Swings & AI Driven Price Forecasts - baoquankhu1.vn
Puma Biotech (PBYI) CFO awarded new RSU and option grants - Stock Titan
Will Puma Biotechnology Inc. stock maintain dividend yieldWeekly Earnings Recap & AI Enhanced Market Trend Forecasts - mfd.ru
PUMA Biotechnology (PBYI) CEO awarded new stock options and RSUs - Stock Titan
Layoff Watch: Can Puma Biotechnology Inc be the next market leaderTrade Ideas & Real-Time Sentiment Analysis - baoquankhu1.vn
Published on: 2026-02-19 23:57:17 - baoquankhu1.vn
Naya Capital Adds Masimo Shares - AOL.com
Puma Biotechnology (PBYI) to Release Earnings on Thursday - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Re - pharmiweb.com
Puma Biotechnology sets Feb. 26 call on 2025 financial results - Stock Titan
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Yahoo Finance
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
Why Puma Biotechnology Inc. stock is popular among millennials2025 Volume Leaders & Risk Controlled Daily Trade Plans - mfd.ru
Fund Flows: Is Puma Biotechnology Inc undervalued by DCF analysisTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 4, 2026 - BioSpace
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule - TradingView
Puma Biotechnology (PBYI) Price Target Increased by 42.86% to 5.10 - Nasdaq
Is Puma Biotechnology Inc. stock a defensive play in 2025Quarterly Performance Summary & Real-Time Chart Pattern Alerts - mfd.ru
Investor Mood: How does Puma Biotechnology Inc. compare to its peersRisk Management & Risk Controlled Stock Alerts - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Buys 159,200 Shares of Puma Biotechnology, Inc. $PBYI - MarketBeat
Revenue Check: Is Puma Biotechnology Inc. stock suitable for long term investing - mfd.ru
Hedge Fund Bets: Is FONAR Corporation exposed to currency risks2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Surprises Report: Will Puma Biotechnology Inc benefit from rate cutsJuly 2025 Action & Verified Short-Term Plans - baoquankhu1.vn
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
Momentum Shift: Can CALC maintain sales growthEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Puma Biotechnology Inc Stock (PBYI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AUERBACH ALAN H | President and CEO |
Jan 06 '26 |
Sale |
5.84 |
16,938 |
98,986 |
7,163,963 |
| HUNT DOUGLAS M | See Remarks |
Jan 07 '26 |
Sale |
5.88 |
5,014 |
29,477 |
155,907 |
| HUNT DOUGLAS M | See Remarks |
Jan 06 '26 |
Sale |
5.84 |
3,973 |
23,218 |
160,921 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 07 '26 |
Sale |
5.88 |
6,405 |
37,655 |
193,284 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 06 '26 |
Sale |
5.84 |
4,540 |
26,532 |
199,689 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):